NovaBridge Biosciences

Phase 1 AI-extracted

Giva

first-line treatment of pancreatic ductal adenocarcinoma

Resolved

98days ago

Phase 1 readout · ~ Mar 31, 2026 estimated

What's at stake Phase 1 trial results for Giva in first-line treatment of pancreatic ductal adenocarcinoma are due ~ Mar 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 6-K verified 15h ago

“Presentation of dose expansion Phase 1b combination data at major medical meeting”

Add to calendar Post on X Reddit

Provenance